Aztreonam (SQ 26,776) is a new synthetic monocyclic P-lactam antibiotic which is specifically active against aerobic gram-negative bacteria. High-pressure liquid chromatographic (HPLC) systems were developed for the quantitative analysis of aztreonam in human, monkey, rat, mouse, and rabbit sera and urine. The HPLC conditions employed for these analyses were a ,uBondapak C18 column, a mobile phase made up of 0.005 M tetrabutylammonium hydrogen sulfate at pH 3.0 and acetonitrile or methanol, UV detection at 293 nm, and a flow rate of 2.0 ml/min. For human sera and urine, the mobile phase was 80%o 0.005 M tetrabutylammonium hydrogen sulfate-0.005M (NH4) 2SO4 and 20% acetonitrile (vol/vol). For the range of sera and urine, HPLC analyses were shown to have excellent detector linearity of aztreonam over a concentration range of 1.0 mg/ml to 0.5 ,ug/ml. Correlation coefficients for plots of aztreonam peak area versus its concentration were -0.990. The detection limit of aztreonam was 1.0 jig/ml in sera and 5.0 ,ug/ml in urine. HPLC and microbiological assays of aztreonam in human sera and urine were in good agreement.
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Aztreonam (SQ 26, 776) (Fig. 1) is a totally synthetic monocyclic ,-lactam antibiotic specifically active against aerobic gram-negative bacteria (6) . It is a member of the monobactams, naturally occurring 3-lactams produced by bacteria (7) . This compound is currently undergoing clinical development, and human pharmacology data have been reported in detail (4, 5) .
The assay of antibiotics in body fluids has traditionally been performed by microbiological assay, but recently high-pressure liquid chromatography (HPLC) has been extensively employed as an alternative procedure (8, 11 Aztreonam. Aztreonam, prepared in our laboratories, was used as either the dipolar ion form shown in Fig. 1 dards were made up in the respective sera over the 1,000-to 0.n-rag/ml concentration range, and both standards and samples were prepared for analysis by using the described preparation technique. The HPLC-analyzed serum standards were used in constructing calibration curves for determining the amount of aztreonam present in serum samples.
HPLC studies of aztreonam in urine. Aztreonam standards were prepared in urine for each of the different species studied over the same concentration range as that used in the preparation of the calibration curve of standards dissolved in the HPLC mobile phase (1,000 to 0.5 iLg/ml). Urine samples were diluted 10-fold with 0.005 M TBAHSO4 (pH 3.0) and analyzed by HPLC under the same conditions as the standards dissolved in the mobile phase. When peak areas of urine standards were plotted on the calibration curve of the HPLC mobile phase dissolved standards, the results showed that the urine sample preparation technique was efficient.
Based on these findings, all of the urine studies were done by preparing standards of aztreonam in the respective urine, preparing the standards and urine samples for HPLC analysis in the manner described above, and using the HPLC-analyzed urine standards in constructing a calibration curve for determining the concentration of aztreonam in the urine samples.
Intravenous dose study of aztreonam in humans. Forty-eight healthy male subjects (six groups with eight subjects per group) took part in the study. The study was carried out as described previously (4) .
Upon receipt of the sera and urine, samples were prepared for HPLC analysis in the manner described earlier and stored at -200C if not immediately analyzed.
Microbiological assay of aztreonam. Aztreonam concentrations in sera and urine were determined by a microbiological agar diffusion method with Escherichia coli SC12155 as the test organism. Serum samples prepared in pooled human sera were initially diluted 1:20 in 0.1 M phosphate buffer (pH 6.0). Subsequent dilutions of test levels were made in a diluent of 5% serum and 95% buffer. The quantitation limit of the method was 0.40 mg/liter. Serum samples containing less than this concentration were assayed in a more sensitive system capable of quantitating aztreonam concentrations as low as 0.06 mg/liter. This latter system involved the extraction of serum standards and samples with methanol, centrifugation, and dilution of the supernatants with 0.1 M phosphate buffer (pH 6.0). Standards were prepared in phosphate buffer (pH 6.0) for the assay of the urine samples. The quantitation limit of the urine assay method was 0.1 mg/liter (4). Table 1 were found to be optimal for the analysis of aztreonam in the various biologibl fluids. The HPLC systems described in TEble 1 for rat, mouse, and monkey sera were also used to confirm the results of serum pharmacokinetic studies on these animals obtained with standard microbiological methods (1). The HPLC system in Table 1 teers from a single-intravenous-dose study of the drug (4, 5) . Chromatograms of a blank human serum sample and a human serum sample containing aztreonam are shown in Fig. 2 . There were no liquid chromatography peaks arising from the blank serum or from the serum of the dosed volunteer which interfered with the assay. A similar comparison of chromatograms shows that the human urine HPLC assay of aztreonam was also free from interfering peaks (Fig. 3) . By using the HPLC conditions given in Table 1 , it was possible to analyze urine and sera from all of the listed animal species for aztreonam without encountering interfering UV-absorbing liquid chromat*phy peaks.
RESULTS

HPLC conditions presented in
The detecW linearity for HPLC assays of aztreonam inWMe different sera and urine over a wide concentration range was excellent. The use of linear regression analysis for the calibration curves of aztreonam concentration versus its peak area for either the sample-prepared sera or urine over an aztreonam concentration range of 1.0 mg/ml to 0.5 ,ug/ml gave correlation coefficients of 20.990. A calibration curve of aztreonam standards dissolved in the HPLC mobile phase over a concentration range of 1.0 mg/ml to 0.05 ,ug/ml gave a correlation coefficient of 1.00 via linear regression analysis. The HPLC system used for these standards was the one listed in Table 1 for human sera and urine. The sample preparation techniques for all sera involving a twofold dilution with acetonitrile before HPLC analysis yielded satisfactory results. By employing the calibration curve of aztreonam standards dissolved in the mobile phase to determine the efficiency of the sample preparation technique, it was found that the amount of aztreonam present in the processed sera over a concentration range of 1.0 mg/ml to 0.5 ,ug/ml was -95 and l103% of the actual amount. The sample preparation technique employed for urine was a 10-fold dilution with pH solved in the mobile phase in determining the efficiency of the urine sample preparation technique over the same 1.0-mg/ml to 0.5-,ug/ml concentration range of aztreonam resulted in recoveries of -96 and <102%.
The HPLC detection limit for the quantitation of aztreonam was 1.0 Fig/ml in sera and 5.0 ,ug/ml in urine. However, the method can be used to qualitatively detect aztreonam at concentrations of cO.5 and -0.025 ,ug/ml. In Fig. 4 an HPLC chromatogram of aztreonam at a concentration of 0.05 ,ug/ml is shown. The time of analysis for either serum or urine was less than 10.0 min per sample. ' There was good agreement between the HPLC and microbiological assays for both serum and urine samples collected from the singleintravenous-dose study in humans. A plot of the median values of the HPLC versus the microbiological assay results for the concentration of aztreonam in sera for a 0.5-g intravenous dose is shown in Fig. 5 . The correlation coefficient obtained via linear regression analysis was 0.997. Figure 6 shows a plot of the median aztreonam values in urine of both assays for the 0.5-g intravenous dose. The correlation coefficient by linear regression analysis was 0.998.
DISCUSSION
In comparing the HPLC assay of aztreonam with a standard microbiological assay, the HPLC assay offers advantages in speed, the need for less sample volume, and the ability to separate chemical entities. HPLC analysis time was less than 10 min per sample and could be performed with as little as 10 ,ul of urine or 50 RIu of serum. Moreover, for the biological fluids studied, the HPLC assay was free from interfering compounds.
Microparticulate reverse-phase columns are widely used for the HPLC analysis of ,-lactam antibiotics (2, 3, 9, 10) . Ion pair chromatography is employed with reverse-phase columns when dealing with a compound which is in an ionic form in the mobile phase and has to be ion paired to be retained on the column. Such methodology has recently been employed in analyzing fermentation broths containing cephalospQrin C and its metabolites (10 human origin allowed aztreonam to be separated from biological fluid components which were atypical to most of the serum and urine samples. A feature of ion pair chromatography is that the dipolar ion of aztreonam, as well as its disodium and dipotassium salts, forms the same chemical species; therefore, the HPLC retention time for all three forms of aztreonam was the same.
The HPLC assays showed excellent detector linearity and accuracy over a 1,000-fold concentration range of aztreonam (from 1.0 mg/ml to 0.5 ,ug/ml). Below 0.5 ,ug/ml, due to detector noise, accuracy decreased.
